10.1186/s13041-017-0300-4 221 ManabeY.WaritaH.MurakamiT.ShioteM.HayashiT.NaganoI.et al
SunLight vs Gala GLP-1: The Bottom Line SunLight is the better default choice because it includes prescribing and clinical oversight, and it starts cheaper for both semaglutide and tirzepatide
The following information is provided for context only and reflects the inclusion criteria used in the 2023 Phase 2 clinical trial (Jastreboff et al., NEJM 2023) these are study-specific criteria and do not represent current UK prescribing standards or predict future NICE commissioning decisions
Future directions and research priorities Future research should prioritize well-controlled human intervention studies integrating GLP-1based pharmacotherapy with defined postbiotic preparations, with explicit assessment of body composition, lean mass preservation, and post-discontinuation weight trajectories
[1] Your provider may adjust your medication dose, modify concurrent medications, or investigate alternative diagnoses